Team

Ángel Álvarez-Prado

Ángel Álvarez-Prado

Principal Investigator

Google Scholar · ORCID · PubMed

Álvarez-Prado graduated in Biotechnology from the Universidad de Salamanca (2012) and obtained his M.Sc. in Molecular Biomedicine (2013) and Ph.D. in Molecular Biosciences (2018, summa cum laude, with Highest Honours) from the Universidad Autónoma de Madrid.

He carried out his doctoral training in Almudena Ramiro's laboratory at the Centro Nacional de Investigaciones Cardiovasculares (Madrid, Spain). There, he studied how a physiological immune response can be derailed and lead to the development of cancer. Specifically, his research focused on understanding how Activation Induced Deaminase (AID) mutational activity, which is critical for antibody diversification, can also be mistargeted to non-immunoglobulin genes, having major implications for lymphomagenesis (Álvarez-Prado et al., J Exp Med, 2018).

In 2019, Álvarez-Prado joined Johanna Joyce's group at the University of Lausanne and Ludwig Institute for Cancer Research (Switzerland) as a postdoctoral fellow to investigate the tumor microenvironment of brain cancers. His research showed that genetically distinct brain metastatic tumors display unique immune microenvironments (Álvarez-Prado et al., Cell Rep Med, 2023); and revealed that RNA sensing, an anti-viral immune mechanism, can be exploited to treat glioblastoma tumors (Álvarez-Prado et al., Cell Rep 2025).

Since 2025, he leads the Translational Cancer Immunogenomics laboratory at the Department of Cancer Research, Luxembourg Institute of Health.

Álvarez-Prado received an ATTRACT grant (2024), Ramón y Cajal grant (2024, declined), ERC Starting Grant (2025) and EMBO Installation Grant (2026) as a Principal Investigator. His postdoctoral research was supported by an EMBO Long-Term Postdoctoral Fellowship (2019), Marie-Sklodowska Curie Actions Individual Fellowship (2020) and the Brain Tumor Charity Future Leaders Program (2022).

Members

Alumni